Natco's maraviroc request set to test India's intentions on compulsory licensing
This article was originally published in Scrip
Natco Pharma's recent request to Pfizer seeking a voluntary licence to Pfizer's HIV entry inhibitor, maraviroc (Selzentry/Celsentri), is expected to serve as a test case on whether India is inclined to invoke compulsory licensing provisions to improve access to expensive drugs that are beyond the means of most of the country's HIV/AIDS patients.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.